These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6222999)

  • 1. Possible dopamine agonist properties of quipazine maleate.
    Feigenbaum JJ; Yanai J; Klawans HL
    Int J Neurosci; 1983; 18(3-4):205-10. PubMed ID: 6222999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparative roles of dopaminergic and serotonergic mechanisms in mediating quipazine induced increases in locomotor activity.
    Feigenbaum JJ; Yanai J; Klawans HL
    J Neural Transm; 1983; 57(1-2):27-37. PubMed ID: 6619829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic activity of quipazine.
    Schechter MD; Concannon JT
    Pharmacol Biochem Behav; 1982 Sep; 17(3):393-7. PubMed ID: 7146043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptic-induced reduction of quipazine-elicited head-twitches in rats: possible involvement of striatal dopaminergic supersensitivity.
    Dall'Olio R; Vaccheri A; Gandolfi O; Roncada P; Montanaro N
    Pharmacol Biochem Behav; 1988 Dec; 31(4):941-4. PubMed ID: 2908069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combined effect of quipazine and haloperidol on plasma prolactin release.
    Feigenbaum J; Yanai J; Klawans HL; Chatterton R
    Int J Neurosci; 1983; 18(1-2):37-40. PubMed ID: 6840980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for the role of noradrenaline in some effects of quipazine.
    Francès H; Lecrubier Y; Puech AJ; Simon P
    Psychopharmacology (Berl); 1980; 67(3):307-10. PubMed ID: 6770410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methysergide blocks the sleep suppressant action of quipazine in rats.
    Fornal C; Radulovacki M
    Psychopharmacology (Berl); 1982; 76(3):255-9. PubMed ID: 6808546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quipazine exacerbation of a hyperkinetic syndrome: involvement of brain dopamine and serotonin.
    Langlais PJ; Gabay S
    J Neurosci Res; 1977; 3(2):135-41. PubMed ID: 563925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A serotonin agonist-antagonist reversible effect on Na+-K+-ATPase activity in the developing rat brain.
    Hernández RJ
    Dev Neurosci; 1982; 5(4):326-31. PubMed ID: 6291893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circling produced by serotonin and dopamine agonists in raphe lesioned rats: a serotonin model.
    Slater P
    Pharmacol Biochem Behav; 1980 Dec; 13(6):817-21. PubMed ID: 7193875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of drugs influencing central 5-hydroxytryptamine mechanisms on amantadine-induced stereotyped behaviour in the rat.
    Dhavare BS; Nandal NV; Balsara JJ; Chandorkar AG
    Indian J Physiol Pharmacol; 1983; 27(1):19-24. PubMed ID: 6682830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of drugs altering striatal dopamine levels on apomorphine induced stereotypy.
    Feigenbaum JJ; Yanai J; Blass RB; Moon B; Klawans H
    Pharmacol Biochem Behav; 1982 Feb; 16(2):235-40. PubMed ID: 7200236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional differences in the sensitivity of cholinergic neurons to dopaminergic drugs and quipazine in the rat striatum.
    Guyenet P; Euvrard C; Javoy F; Herbert A; Glowinski J
    Brain Res; 1977 Nov; 136(3):487-500. PubMed ID: 922497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of imipramine and serotonin-2 agonists and antagonists on serotonin-2 and beta-adrenergic receptors following noradrenergic or serotonergic denervation.
    Eison AS; Eison MS; Yocca FD; Gianutsos G
    Life Sci; 1989; 44(19):1419-27. PubMed ID: 2785627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of drugs influencing central serotonergic mechanisms on methamphetamine-induced stereotyped behavior in the rat.
    Balsara JJ; Jadhav JH; Muley MP; Chandorkar AG
    Psychopharmacology (Berl); 1979 Sep; 64(3):303-7. PubMed ID: 116272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tonic immobility in domestic fowl: anticataleptic effects of quipazine.
    Wallnau LB
    Pharmacol Biochem Behav; 1980 Mar; 12(3):347-52. PubMed ID: 7190287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amphetamine stereotypy in cats and neurotransmitter interactions in the caudate nucleus. III. Effects of intracaudate injections of quipazine, cyproheptadine and electrical stimulation of the raphe dorsal nucleus.
    Moyanova SG; Rousseva SP
    Acta Physiol Pharmacol Bulg; 1989; 15(3):43-9. PubMed ID: 2574932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of quipazine and methysergide on play in juvenile rats.
    Normansell L; Panksepp J
    Pharmacol Biochem Behav; 1985 May; 22(5):885-7. PubMed ID: 2989950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists.
    LaHoste GJ; Marshall JF
    Behav Brain Res; 1990 May; 38(3):233-42. PubMed ID: 1973041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced head-twitch response to quipazine of rats previously treated with methiothepin: possible involvement of dopaminergic system.
    Dall'Olio R; Vaccheri A; Montanaro N
    Pharmacol Biochem Behav; 1985 Jul; 23(1):43-8. PubMed ID: 2994121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.